Abbott Laboratories Forecast, price target & analysts
Abbott Laboratories Target price 2025 - Analyst rating & recommendation
Abbott Laboratories Classifications & Recommendation:
Abbott Laboratories Price Target
| Target Price | $138.29 |
| Price | $129.89 |
| Potential |
6.46%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Abbott Laboratories 2026 .
The average Abbott Laboratories target price is $138.29.
This is
6.46%
register free of charge
$160.00
23.18%
register free of charge
$117.00
9.92%
register free of charge
|
|
| A rating was issued by 28 analysts: 19 Analysts recommend Abbott Laboratories to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Abbott Laboratories stock has an average upside potential 2026 of
6.46%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 41.95 | 44.34 |
| 4.59% | 5.69% | |
| EBITDA Margin | 24.00% | 26.81% |
| 0.53% | 11.70% | |
| Net Margin | 31.54% | 15.34% |
| 124.07% | 51.36% |
23 Analysts have issued a sales forecast Abbott Laboratories 2025 . The average Abbott Laboratories sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Abbott Laboratories EBITDA forecast 2025. The average Abbott Laboratories EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Abbott Laboratories Analysts have issued a net profit forecast 2025. The average Abbott Laboratories net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 7.64 | 3.93 |
| 134.36% | 48.56% | |
| P/E | 33.18 | |
| EV/Sales | 5.27 |
12 Analysts have issued a Abbott Laboratories forecast for earnings per share. The average Abbott Laboratories <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Abbott Laboratories stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Abbott Laboratories...
Current Abbott Laboratories Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Jan 27 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Jan 23 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 23 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Jan 23 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
